Additional research may show potential for CBD as a therapeutic agent for hepatocellular carcinoma
Cannabinoid (CBD) may be an effective treatment for hepatocellular carcinoma (HCC). Cannabinoid receptor 2 (CB2 receptor) has demonstrated anti-tumor behavior in other tumor types. In a new study, HCC cells treated with MDA19, a molecule that binds to the CB2 receptor, grew more slowly than untreated cells. With CBD also binding to the CB2 receptor, there may be precedent for research on the potential of CBD as a treatment for HCC.
CED Foundation Google Drive: http://bit.ly/2YRTyhl
Read Here or Download:
MDA19, a novel CB2 agonist, inhibits hepatocellular carcinoma partly through inactivation of AKT signaling pathwayDownload






